Cardiff Oncology, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CRDF, updated each market day.
CRDF AI Sentiment
AI sees no strong directional signal for Cardiff Oncology, Inc. Common Stock stock over the next 10 market days.
Prediction date: Aug. 31, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Sector
Exchange
Market Cap
$76,713,895
Cap Tier
Employees
31
Headquarters
SAN DIEGO, CA
Listed Since
May 22, 1997
Website
CRDF Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRDF Volatility
Cardiff Oncology, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
